TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
PFE

Pfizer Inc

Healthcare · Drug Manufacturers - General

28.70$ +0.9% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios PFE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
17.9 76.3 – – 38.6 18.8 18.4 12.8 14.8 18.2 21.5 31.7
2.7 2.7 2.8 2.8 2.7 2.4 2.3 2.2 2.3 2.3 2.5 2.2
1.9 1.8 1.7 1.8 1.8 1.7 1.6 1.6 1.6 1.6 1.8 1.6
3.6 3.9 4.1 4.0 3.8 3.4 3.3 3.1 3.3 3.3 3.5 3.1
13.6 24.6 31.1 41.4 16.7 10.3 10.3 8.7 9.7 12.2 13.3 15.8
22.9 33.9 31.0 33.2 20.0 15.4 12.9 11.1 14.0 15.6 17.0 12.5
4.4% 2.9% 3.2% 3.0% 5.0% 6.5% 7.8% 9.0% 7.1% 6.4% 5.9% 8.0%
Margins
55.5% 52.1% 51.8% 49.1% 58.7% 66.8% 66.9% 67.3% 71.2% 70.3% 69.3% 71.3%
16.4% 7.9% 4.6% 3.9% 16.8% 26.9% 27.5% 29.6% 27.8% 24.7% 23.4% 25.1%
15.2% 3.6% -0.5% -4.6% 7.1% 12.6% 12.6% 16.8% 15.6% 12.4% 11.8% 6.8%
11.9% 8.1% 9.2% 8.6% 13.6% 15.5% 18.0% 19.5% 16.5% 14.5% 15.0% 17.2%
Returns
10.8% 2.4% -0.3% -3.0% 4.6% 9.1% 8.7% 12.1% 10.6% 9.0% 8.3% 5.1%
4.9% 0.9% -0.1% -1.2% 1.9% 3.8% 3.8% 5.2% 4.7% 3.7% 3.6% 2.2%
Balance Sheet & Debt
60,448 69,006 68,464 67,625 65,525 62,606 59,861 59,287 59,505 63,149 62,027 62,218
3.3 7.3 9.4 12.3 4.7 3.0 3.0 2.6 2.8 3.8 3.7 4.9
45.1% 39.3% 41.7% 40.6% 42.0% 41.3% 43.4% 43.0% 44.5% 41.5% 43.4% 42.4%
0.7 0.8 0.7 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7
Per Share
1.85 0.38 -0.05 -0.46 0.75 1.41 1.38 1.88 1.72 1.37 1.31 0.76
12.22 10.50 9.77 9.87 10.59 11.16 10.94 11.19 10.99 11.01 11.05 11.18
17.17 15.76 16.20 15.40 16.18 15.47 15.82 15.54 16.24 15.21 15.72 14.95
1.45 0.85 0.90 0.84 1.44 1.72 1.96 2.18 1.82 1.60 1.65 1.93

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?